Nutritional and lifestyle supportive care recommendations for ...
Optimizing GLP-1 Therapy for Obesity with Nutrition and Food is Medicine Obesity is a chronic disease that affects nearly 100 million U.S. adults.2 Glucagon-like peptide 1 receptor agonists and combination medications such as semaglutide (Ozempic, Wegovy), liraglutide (Saxenda), and tirzepatide (Zepbound)—collectively referred to in this fact sheet as GLP -1s—can help patients lose ...
Nutritional priorities to support GLP
Glucagon-like peptide 1 receptor agonists and combination medications (hereafter collectively referred to as GLP-1s ) are shifting the treatment landscape for obesity. However, real-world challenges and limited clinician and public knowledge on nutritional and lifestyle interventions can limit GLP-1 efficacy, equitable results, and cost-effectiveness.

News Major Medical Groups Release First Joint Nutrition Guidelines for GLP-1s Four leading medical organizations publish comprehensive nutritional guidelines for GLP-1 therapy , emphasizing the importance of personalized nutrition and lifestyle support.
Nutritional Priorities to Support GLP
Washington, D.C. (May 30, 2025) - Four leading organizations in lifestyle medicine, obesity medicine, and nutrition—the American College of Lifestyle Medicine (ACLM), the American Society for Nutrition (ASN), the Obesity Medicine Association (OMA), and The Obesity Society (TOS)—have jointly released a clinical advisory titled "Nutritional Priorities to Support GLP-1 Therapy for Obesity ...

Explore key nutritional priorities to support GLP‑1 therapy for obesity, helping patients optimize treatment outcomes and overall health.
Nutritional priorities to support GLP
Glucagon-like peptide 1 receptor agonists and combination medications ( GLP-1s ) are shifting the treatment landscape for obesity. However, real-world challenges and limited clinician and public knowledge on nutritional and lifestyle interventions can ...

on nutritional and lifestyle interventions can limit GLP-1 efficacy, equitable results, and cost-effectiveness. Objectives: We aimed to identify pragmatic priorities for nutrition and other lifestyle interventions relevant to GLP-1 treatment of obesity for the practicing clinician.
PDF Nutritional Priorities to Support GLP
Collectively, they have issued evidence based, consensus driven guidance to help clinicians optimize nutritional health of patients using GLP-1 receptor agonists. GLP-1 therapies have demonstrated significant benefits, including 8 to 22% average weight loss and improvements in metabolic and cardiovascular health.
This narrative review explores and summarizes existing literature on the challenges associated with nutrition intake in people with obesity taking GLP-1 based therapies and practical applications of nutrition and lifestyle interventions for the management of these individuals to ensure their best long-term health outcomes.